Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Chikungunya Virus Vaccine Trial in Healthy Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
ClinicalTrials.gov Identifier:
NCT01489358
First received: December 7, 2011
Last updated: June 9, 2016
Last verified: March 2016
  Purpose

Background:

- Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death. But the joint pain, which may be directly related to the infecting virus, may be severe and last for several months. CHIKV outbreaks are most common in Africa, India, and Asia. A new experimental vaccine for CHIKV has been developed, and researchers are testing it in healthy adults. Participants cannot develop CHIKV from this vaccine.

Objectives:

- To test the safety and effectiveness of a Chikungunya virus vaccine.

Eligibility:

- Healthy individuals between 18 and 50 years of age.

Design:

  • This study, including vaccine doses and followup tests, will last about 44 weeks. Participants will have three vaccination visits, six followup clinic visits, and three telephone contacts during this study. Vaccination visits will take about 4 hours. Most other clinic visits will usually take 2 hours. The telephone contacts will take about 15 minutes.
  • Participants will be screened with a physical exam and medical history. Blood samples will also be collected.
  • Participants will be assigned to one of three dose groups. Information about doses will be provided before the start of the vaccinations.
  • Vaccine injections will be given at the start of the study, at 4 weeks, and at 20 weeks. Participants will be asked to keep an eye on the injection site for 7 days and to notify researchers if there are any side effects.
  • Participants will be monitored throughout the study with blood samples and clinic visits.

Condition Intervention Phase
Viral Vaccines
Chikungunya Fever
Chikungunya Virus Infection
Biological: VRC-CHKVLP059-00-VP
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination [ Time Frame: 7 days after the first vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.

  • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Second Vaccination [ Time Frame: 7 days after the second vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after second vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.

  • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Third Vaccination [ Time Frame: 7 days after the third vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after third vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.

  • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Vaccination [ Time Frame: 7 days after any vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after any vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.

  • Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination [ Time Frame: 7 days after the first vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all systemic symptoms is the number reporting one or more systemic symptom at any severity.

  • Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Second Vaccination [ Time Frame: 7 days after the second vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after second vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all systemic symptoms is the number reporting one or more systemic symptom at any severity.

  • Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Third Vaccination [ Time Frame: 7 days after the third vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after third vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all systemic symptoms is the number reporting one or more systemic symptom at any severity.

  • Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any Vaccination [ Time Frame: 7 days after any vaccination ] [ Designated as safety issue: Yes ]
    Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after any vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all systemic symptoms is the number reporting one or more systemic symptom at any severity.

  • Number of Subjects With an Any Abnormal Laboratory Result [ Time Frame: 44 weeks after first vaccination ] [ Designated as safety issue: Yes ]
    Blood samples were collected for chemistry, CBC with differential, at baseline and weeks 2, 4, 6, 8, 20, 22, 24 and 44

  • Number of Subjects Reporting Serious Adverse Events [ Time Frame: 44 weeks after first vaccination ] [ Designated as safety issue: Yes ]
    Serious adverse events were collected at each study visit from the time of first vaccination through the final study visit at 44 weeks after the first vaccination.

  • Number of Subjects Reporting 1 or More Unsolicited Adverse Event [ Time Frame: 28 days after each vaccination ] [ Designated as safety issue: Yes ]

    Unsolicited adverse events were recorded from enrollment through 28 days after the second vaccination; and from the third vaccination through 28 days after this vaccination.

    Between and after the indicated time periods, through the last expected study visit (i.e., 24 weeks after the third vaccination), only SAEs and new chronic medical conditions were recorded. The number of unsolicited events reported for Group 3 here is lower than the total number of adverse events in the Adverse Event Module, which reports both solicited and unsolicited adverse events.



Secondary Outcome Measures:
  • Chikungunya Antigen-specific ELISA Geometric Mean Titer (GMT) [ Time Frame: 24 weeks after the first vaccination ] [ Designated as safety issue: No ]
    ELISA titer (strain 37997) For ELISA, week 0 values were used to background correct titres for subsequent weeks.

  • Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) [ Time Frame: Pre-vaccination (Week 0) ] [ Designated as safety issue: No ]
    Neutralisation IC50 titre (strain OPY1)

  • Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) [ Time Frame: 24 weeks after the first vaccination ] [ Designated as safety issue: No ]
    Neutralisation IC50 titre (strain OPY1)


Enrollment: 25
Study Start Date: December 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
Biological: VRC-CHKVLP059-00-VP
VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
Experimental: Group 2
Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
Biological: VRC-CHKVLP059-00-VP
VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
Experimental: Group 3
Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
Biological: VRC-CHKVLP059-00-VP
VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus

Detailed Description:

This is a Phase I, open-label, dose-escalation study to examine the safety, tolerability, and immune response to a Virus-Like Particle (VLP) Chikungunya Virus (CHIKV) vaccine in healthy adults ages 18 to 50 years old. The plan is for 25 subjects to receive 3 intramuscular vaccine injections at weeks 0, 4, and 20. The three groups will be enrolled sequentially starting with the lowest dose of 10 micrograms per injection in Group 1.

The hypothesis is that the vaccine is safe and induces immune responses to CHIKV. The primary objective is to evaluate the safety and tolerability of the investigational vaccine, VRC-CHKVLP059-00-VP, at three dosages, 10 micrograms (mcg), 20 mcg, and 40 mcg, in healthy adults. The secondary objective is to evaluate the antibody response against CHIKV VLPs four weeks after the third vaccine injection. The exploratory objectives relate to antigen-specific humoral and cellular immune responses throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

A participant must meet all of the following criteria:

  1. 18 to 50 years old
  2. Available for clinical follow-up through Week 44
  3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
  4. Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly
  5. Able and willing to complete the informed consent process
  6. Willing to donate blood for sample storage to be used for future research
  7. In good general health, with a BMI less than or equal to 40, without clinically significant medical history, and has satisfactorily completed screening
  8. Physical examination and laboratory results without clinically significant findings within the 56 days prior to enrollment

    Laboratory Criteria within 56 days prior to enrollment:

  9. Hemoglobin greater than or equal to11.5 g/dL for women; greater than or equal to13.5 g/dL for men
  10. WBC: 3,000-12,000 cells/mm(3).
  11. Differential either within institutional normal range or accompanied by physician approval
  12. Total lymphocyte count: greater than or equal to 800 cells/mm(3)
  13. Platelets = 125,000-500,000/mm(3)
  14. Alanine aminotransferase (ALT) less than or equal to 1.25 times upper limit of normal range
  15. Serum creatinine less than or equal to1x upper limit of normal (less than or equal to1.3 mg/dL for females; less than or equal to1.4 mg/dL for males).
  16. Negative FDA-approved HIV blood test

    Female-Specific Criteria

  17. Negative Beta-HCG pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential
  18. A woman of childbearing potential must agree to use an effective means of birth control from at least 21 days prior to enrollment through 12 weeks after last study vaccination

EXCLUSION CRITERIA:

A participant will be excluded if one or more of the following conditions apply:

Female-Specific Criteria

  1. Woman who is breast-feeding or planning to become pregnant during the time projected for individual study participation
  2. Systemic immunosuppressive medications or cytotoxic medications within 12 weeks prior to enrollment [with the exceptions that a short course of corticosteroids (less than or equal to10 days duration or a single injection) for a self-limited condition at least 2 weeks prior to enrollment will not exclude study participation]
  3. Blood products within 16 weeks prior to enrollment
  4. Immunoglobulin within 8 weeks prior to enrollment
  5. Prior vaccinations with an investigational CHIKV vaccine
  6. Investigational research agents within 4 weeks prior to enrollment
  7. Live attenuated vaccines within 4 weeks prior to enrollment
  8. Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 2 weeks prior to enrollment
  9. Current anti-TB prophylaxis or therapy

    Subject has a history of any of the following clinically significant conditions:

  10. A history of confirmed or suspected CHIKV infection
  11. A history of immune-mediated or clinically significant arthritis
  12. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator
  13. Hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema
  14. Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that is expected to require the use of oral or intravenous corticosteroids
  15. Diabetes mellitus (type I or II), with the exception of gestational diabetes
  16. Idiopathic urticaria within the past year
  17. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  18. Malignancy that is active, or treated malignancy for which there is not reasonable assurance of sustained cure, or malignancy that is likely to recur during the period of the study
  19. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years
  20. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
  21. Psychiatric condition that may preclude compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, a history of suicide plan or attempt
  22. Any medical condition (such as thyroid disease or hypertension that are not well controlled by medication, or viral hepatitis) that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489358

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: Julie E Ledgerwood, D.O. National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01489358     History of Changes
Other Study ID Numbers: 120041  12-I-0041 
Study First Received: December 7, 2011
Results First Received: March 11, 2016
Last Updated: June 9, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institutes of Health Clinical Center (CC):
Vaccine-Mediated Protection
Antibody Response
Chikungunya Virus
Immune Response
Healthy Volunteer
Humoral Inmunity
Virus-like Particles

Additional relevant MeSH terms:
Virus Diseases
Chikungunya Fever
Alphavirus Infections
Togaviridae Infections
RNA Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 27, 2016